Bortezomib Sensitizes Primary Human Astrocytoma Cells of WHO Grades I to IV for Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Clinical Cancer Research

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-0251PMID 17545549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer‐specific apoptosis within a therapeutic window

  2007cited by this paper
• NF-κB-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition

  2007cited by this paper
• The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

  2006cited by this paper
• Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells.

  2006cited by this paper
• Persistent inhibition of FLIPL expression by lentiviral small hairpin RNA delivery restores death-receptor-induced apoptosis in neuroblastoma cells

  2006cited by this paper
• The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells

  2006cited by this paper
• Preclinical Differentiation between Apparently Safe and Potentially Hepatotoxic Applications of TRAIL Either Alone or in Combination with Chemotherapeutic Drugs

  2006cited by this paper
• Apoptosis: a relevant tool for anticancer therapy.

  2006cited by this paper
• mTOR Controls FLIPS Translation and TRAIL Sensitivity in Glioblastoma Multiforme Cells

  2005cited by this paper
• Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1

  2005cited by this paper
• Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL

  2005cited by this paper
• Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)

  2005cited by this paper
• The Proteasome Inhibitor Bortezomib (Velcade) Sensitizes Some Human Tumor Cells to Apo2L/TRAIL‐Mediated Apoptosis

  2005cited by this paper
• TRAIL and its receptors as targets for cancer therapy

  2004cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies.

  2004cited by this paper
• Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells

  2004cited by this paper
• Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs

  2004cited by this paper
• TRAIL Triggers Apoptosis in Human Malignant Glioma Cells Through Extrinsic and Intrinsic Pathways

  2003cited by this paper
• Bortezomib Treatment for Multiple Myeloma

  2003cited by this paper
• The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

  2003cited by this paper
• State-of-the-art treatment of high-grade brain tumors.

  2003cited by this paper
• The WHO Classification of Tumors of the Nervous System

  2002cited by this paper
• Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Death-inducing Signaling Complex and Its Modulation by c-FLIP and PED/PEA-15 in Glioma Cells*

  2002cited by this paper
• BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

  2001cited by this paper
• Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

  2000cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery

  1998cited by this paper
• Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.

  1996cited by this paper

• Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines

  2025cites this paper
• Marizomib in the therapy of brain tumors—how far did we go and where do we stand?

  2025cites this paper
• TRAIL-induced apoptosis and proteasomal activity - Mechanisms, signalling and interplay.

  2024cites this paper
• Stem cells for the treatment of glioblastoma: a 20-year perspective

  2021cites this paper
• Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers

  2021cites this paper
• Fucosylation in Urological Cancers

  2021cites this paper
• Chemotherapeutic Agents Sensitize Resistant Cancer Cells to the DR5-Specific Variant DR5-B More Efficiently Than to TRAIL by Modulating the Surface Expression of Death and Decoy Receptors

  2020cites this paper
• Proteasome inhibition for the treatment of glioblastoma

  2020cites this paper
• Harnessing Human Stem Cells for the Treatment of Glioblastoma – Twenty Year Perspective – Review of Preclinical and Clinical Studies: 2000–2020

  2020cites this paper
• An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability

  2019cites this paper
• The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma

  2019cites this paper
• Downregulation of SKP2 in Papillary Thyroid Cancer Acts Synergistically With TRAIL on Inducing Apoptosis via ROS

  2018cites this paper
• The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells

  2018cites this paper
• TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells

  2016cites this paper
• Generation of colo rectal cancer targeting TRAIL fusion proteins and a mesenchymal stem cell line for in situ expression of these proteins

  2016cites this paper
• Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma

  2016cites this paper
• Onto better TRAILs for cancer treatment

  2016cites this paper
• Withanolide E sensitizes renal carcinoma cells to TRAIL-induced apoptosis by increasing cFLIP degradation

  2015cites this paper
• Molecular mechanisms of apoptosis and roles in cancer development and treatment.

  2015cites this paper
• Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.

  2015cites this paper
• WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma.

  2015cites this paper
• Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5

  2015cites this paper
• New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinants.

  2015cites this paper
• SMAC-MIMETIC- AND TRAIL- BASED COMBINATIONS AS THERAPEUTIC STRATEGIES FOR KRAS-MUTATED CANCERS

  2015cites this paper
• Targeted induction of apoptosis in glioblastoma multiforme cells by an MRP3-specific TRAIL fusion protein in vitro

  2014cites this paper
• Glioma-Associated Proteases

  2014cites this paper
• Synthesis of diethylamino-curcumin mimics with substituted triazolyl groups and their sensitization effect of TRAIL against brain cancer cells.

  2014cites this paper
• PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma

  2014cites this paper
• Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic

  2014cites this paper
• The TRAIL Sensitization Effect of Substituted Triazolyl Curcumin Mimics Against Brain Cancer Cells

  2014cites this paper
• Bortezomib Sensitizes Primary Meningioma Cells to TRAIL-Induced Apoptosis by Enhancing Formation of the Death-Inducing Signaling Complex

  2014cites this paper
• Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4

  2014cites this paper
• Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies

  2013cites this paper
• Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  2013cites this paper
• Targeting c-FLIP in cancer.

  2013cites this paper
• Central nervous system multiple myeloma – potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains

  2013cites this paper
• Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma

  2013cites this paper
• Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?

  2013influential citation
• Harnessing Death Receptor Signaling for Cancer Treatment

  2013cites this paper
• Proteasomal regulation of caspase-8 in cancer cell apoptosis

  2013cites this paper
• Integrating immune cell functions and apoptosis-based therapies for the treatment of ovarian cancer

  2013influential citation
• Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer

  2013cites this paper
• PROTEASOME REGULATION OF CASPASE-8: SIGNIFICANCE IN CANCER

  2012cites this paper
• New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy

  2012cites this paper
• Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis

  2012cites this paper
• The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.

  2012cites this paper
• Fucosylation Is a Promising Target for Cancer Diagnosis and Therapy

  2012cites this paper
• Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity

  2012cites this paper
• Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling

  2012cites this paper
• Sensitization of (colon) cancer cells to death receptor related therapies

  2012cites this paper
• Cytochalasin D, a tropical fungal metabolite, inhibits CT26 tumor growth and angiogenesis.

  2012cites this paper
• Tumour-selective apoptosis : identification of NMHCIIa as novel death receptor interactor regulating the response to TRAIL

  2012cites this paper
• Inhibition of Heat Shock Protein Response Enhances PS-341-Mediated Glioma Cell Death

  2012cites this paper
• TRAIL-receptor and proteasome targeted therapies in non-small cell lung cancer

  2011influential citation
• Preclinical Development Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL , Mediated by Inhibition of the NFk B Signaling Pathway

  2011cites this paper
• Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCε-dependent downregulation of AKT and XIAP expressions.

  2011cites this paper
• Novel therapeutic venues for glioblastoma: novel rising preclinical treatment opportunities

  2011cites this paper
• Bortezomib Sensitizes Malignant Human Glioma Cells to TRAIL, Mediated by Inhibition of the NF-κB Signaling Pathway

  2011cites this paper
• Treatment Resistance Mechanisms of Malignant Glioma Tumor Stem Cells

  2011cites this paper
• Malignant Glioma Cells: Role of Trail-Induced Apoptosis

  2011cites this paper
• Bortezomib Primes Glioblastoma, Including Glioblastoma Stem Cells, for TRAIL by Increasing tBid Stability and Mitochondrial Apoptosis

  2011influential citation
• Towards personalized therapy for patients with glioblastoma

  2011cites this paper
• Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

  2011cites this paper
• The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.

  2011cites this paper
• Targeting the extrinsic apoptosis signaling pathway for cancer therapy

  2011cites this paper
• Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents.

  2011cites this paper
• High-Grade Astrocytomas

  2011cites this paper
• Targeting apoptosis in cancer cells : improving TRAIL death receptor signaling

  2011cites this paper
• The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis

  2011cites this paper
• Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts.

  2011influential citation
• TRAILing death in cancer.

  2010cites this paper
• Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.

  2010cites this paper
• Capsaicin sensitizes malignant glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and survivin downregulation.

  2010cites this paper
• Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib

  2010cites this paper
• Bortezomib Sensitizes Human Renal Cell Carcinomas to TRAIL Apoptosis through Increased Activation of Caspase-8 in the Death-Inducing Signaling Complex

  2010cites this paper
• TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5

  2010cites this paper
• Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis

  2010cites this paper
• Fucosylation and gastrointestinal cancer.

  2010cites this paper
• Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL–Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways

  2010cites this paper
• The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade

  2010cites this paper
• Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

  2010cites this paper
• Therapeutic exploitation of apoptosis and autophagy for glioblastoma.

  2010cites this paper
• HARPΔ111-136 enhances radiation-induced apoptosis of U87MG glioblastoma by induction of the proapoptotic protein CHOP.

  2010cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease.

  2010cites this paper
• Review: On TRAIL for malignant glioma therapy?

  2010cites this paper
• Improving the response to molecular targeting of the TRAIL death receptors in colon cancer cells

  2010cites this paper
• On TRAIL for glioma therapy

  2010cites this paper
• University of Groningen On TRAIL for glioma therapy ?

  2010cites this paper
• Chapter 2 On TRAIL for malignant glioma therapy ?

  2010cites this paper
• SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo

  2009cites this paper
• KAAD-cyclopamine augmented TRAIL-mediated apoptosis in malignant glioma cells by modulating the intrinsic and extrinsic apoptotic pathway.

  2009cites this paper
• Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells.

  2009cites this paper
• Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling.

  2009cites this paper
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1.

  2009cites this paper
• Cancer Therapy : Preclinical SC 68896 , a Novel Small Molecule Proteasome Inhibitor , Exerts Antiglioma Activity In vitro and In vivo

  2009cites this paper
• Preclinical Therapy SC 68896 , a Novel Small Molecule Proteasome Inhibitor , Exerts Antiglioma Activity In vitro and In vivo

  2009cites this paper
• From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.

  2009cites this paper
• Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies

  2009cites this paper
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

  2009cites this paper